Pharmaceutical Organization Developing new antiretroviral drugs for HIV/AIDS patients infected with hepatitis C virus

Pharmaceutical Organization Developing new antiretroviral drugs for HIV/AIDS patients infected with hepatitis C virus

Today (30 November 2022) Ph.D. Nantakan Suwanpidokkul Deputy Director of the Government Pharmaceutical Organization (GPO) discusses the research and development of the GPO for people with HIV/AIDS. On World AIDS Day on December 1, the Ministry of Public Health recognizes the importance of developing antiretroviral drug research for HIV/AIDS patients. come continuously with the development of antiretroviral drugs to keep pace with the situation and new treatment guidelines as well as drug development in both single drug formulations and combination drug formulations for adults and children By taking into account the convenience of the patient taking the drug continuously. to prevent drug resistance Including the development of drug efficacy to cover treatment even among patients with drug resistance.

The deputy director of the PPP said that in the past it was found that there were people infected with HIV / AIDS. together with many hepatitis C infections that do not have access to drug therapy. Because it is a drug that has to be imported, which has a high price. Therefore, the DOH has started research and development of the first generic anti-HCV drug since 2012, namely Ribavirin tablets, 400 and 200 mg, used in combination with pecinterfer injection. Ron (Pegylated interferon; Peg-IFN). Makes the patient uncomfortable in drug administration. Therefore switched to using drugs in the form of oral drugs The Ministry of Public Health has therefore researched and developed a well-known combination drug formula. GPO-Hep C tablets, which are a combination of 400 mg Sofosbuvir tablets and Velpatasvir tablets. Pangenotypic direct-acting antiviral agents (DAAs) are available for the treatment of all strains of hepatitis C virus infection. Increase the convenience of taking medicines for patients. Resulting in better treatment efficiency and reducing the problem of drug resistance. By reducing the number of pills to be taken from 2 tablets 1 time per day from the original drug formula to 1 tablet 1 time per day. It has been used to treat infected people and patients in the National Health Security System. and patients in the social security system can use the service in the hospital according to the right to receive treatment free of charge

Dr. Nuntakarn said that the development of such drugs It is like a gift that Apor.M. is determined to give to infected people and patients. To have access to treatment effectively and equally, in line with the concept of organizing the “Thian Song Jai” event on the occasion of World AIDS Day on December 1, 2022, which the Thai Red Cross Society has scheduled to be held annually. Between 1-3 December 2022 to raise awareness of the AIDS problem. and cooperation, prevention, correction, as well as building understanding of infected people By organizing the event under the concept of “EQualize, make it equal” at Rattana Wittayapat Building, M1 Floor, Chulalongkorn Hospital, Thai Red Cross Society, where the PPP participated in presenting the development of new antiviral drugs. To provide infected people and Thai patients with access to effective medicines and treatments. leading to a better quality of life

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick